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We have analyzed the effects of several natural compounds related to avarols and avarones on the catalytic functions of human immunodeficiency 
virus type 1 (HIV-l) reverse transcriptase (RT). The most potent substances, designated as avarone A,B and E and avarol F, inhibited indiscrimina- 
tely the enzymatic activities of HIV-l RT, namely the RNA-dependent and DNAdependent DNA polymerase as well as the ribonuclease H. The 
inhibition of the DNA polymerase activity was found to be noncompetitive with respect o either the template-primer o  the deoxynucleotide- 
triphosphate. These studies uggest that the hydroxyl group at the ortho position to the carbonyl group at the quinone ring is involved in blocking 
the RT activity. The identification of the active site of the inhibitors will hopefully lead to the rational design of new potent anti-HIV drugs. 
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1. INTRODUCTION 
Active inhibitors of human immunodeficiency virus 
(HIV) may be suitable for the chemotherapy of ac- 
quired immunodeficiency syndrome (AIDS), the 
devastating human disease caused by HIV [ 1,2]. One of 
the ideal specific targets for chemotherapeutic treat- 
ment of HIV is the viral encoded enzyme reverse 
transcriptase (RT). This enzyme has a key role in the 
early stages of HIV infection and is responsible for con- 
verting the viral genomic RNA into proviral double- 
stranded DNA which is subsequently integrated into 
the host chromosomal DNA. Reverse transcriptases are 
unique to retroviruses and no cellular homologues are 
known (except those associated with endogenous 
retroviruses and retrotransposons). The search for anti- 
HIV RT drugs and a detailed study on the mechanism 
of the molecular and catalytic properties of reverse 
transcriptase (thus contributing towards the design of 
new drugs) require the availability of relatively large 
quantities of purified active protein. For this reason, 
several recombinant RT expression systems have been 
developed in bacteria, leading to the synthesis of 
substantial amounts of highly active, soluble and nearly 
authentic HIV-l RT [3-51. This recombinant enzyme is 
in many catalytic features indistinguishable from the 
enzyme found in virions [3,6]. 
leads towards finding new pharmaceutically useful 
agents. In direct response to these encouraging results, 
we have decided to screen different marine natural pro- 
ducts for their anti-HIV-RT activities. The presence of 
large amounts of recombinant HIV-l RT combined 
with the convenient accessibility of various natural pro- 
ducts, isolated from the Red Sea fauna (mainly sponges 
and corals) have enabled us to conduct a wide survey 
for specific inhibitors of this enzyme. During the course 
of this study we found that three novel natural products 
derivatives of the sesquiterpenoid avarol, isolated from 
the marine sponge Dysidea cinerea Keller from the Gulf 
of Eilat in the Red Sea, are potent in vitro inhibitors of 
HIV-l RT. 
2. MATERIALS AND METHODS 
Over the past few years, large scale screening of 
marine species have produced a number of exciting 
Avarol and avarone derivatives designated as A-F as shown in the 
structural formulas in Fig. 1 were a generous gift of Professor Y. 
Kashman. Apart from avarone A that is a known compound, the 
other 4 are novel secondary proferan metabolites (Professor 
Kashman, personal communication). The substances were dissolved 
in 1OOvo dimethylsulphoxide (DMSO) to final concentrations of 
10 mg/ml. The final DMSO concentration in the enzymatic assays 
was I%, a concentration that did not affect the different RT- 
associated activities. 
HIV-1 reverse transcriptase was a recombinant protein expressed in
E. coli with an apparent molecular weight of 66 kDa (that differs 
from the RT found in HIV-l only in two additional amino terminal 
amino acids residues [3]). The HIV-l RT was purified to homogenei- 
ty according to Clark et al. (71. 
2.1. Enzyme assays 
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Fig. 1. Structural formulas of avarol and avarone derivatives. 
propriate substrate and subsequently incubated at 37°C for 30 min. 
Inhibition of enzyme activity was calculated relative to the linear 
reaction rates observed where no drug was added. The definition of 
the enzymatic activities is as follows: One unit of DNA polymerase 
activity is defined as the amount of enzyme that catalyzes the incor- 
poration of 1 pmol of dGTP into the DNA product after 30 min at 
37”C, under the standard assay conditions (see below). One unit of 
the RNase H activity is the amount of enzyme that catalyzes the 
hydrolysis of 1 pmol AMP after 30 min at 37”C, under the assay con- 
ditions. 
RNase H assay was performed by measuring the release of radioac- 
tively labelled molecules from [3H]poly(rA). poly(dT) into the 
trichloroacetic acid soluble fraction. The assay was carried out in a 
final volume of 0.1 ml containing 50 mM Tris-Cl (pH 8.0), 50 mM 
KCI, 8 mM MgC12, 2.5 mM dithiothreitol and approximately 
110 pmol of total nucleotides of [3H]poly(rA)-poly(dT). The reac- 
tions were terminated by transfer onto ice followed by the addition 
of 250 Kg herring sperm carrier DNA and 0.6 ml 10% (w/v) ice-cold 
TCA. After 5 min on ice the solutions were centrifuged at 10000 X 
g for 5 min and the supernatants were counted. The substrate [‘H]po- 
ly(rA) . poly(dT) was prepared according to the procedure described 
by Hizi and Joklik [8]. 
R T-associated DNA polymerme assays were carried out in a final 
volume of 0.1 ml containing 25 mM Tris-Cl (pH 8.0), 40 mM KCI, 
8 mM MgC12, 3 mM dithiothreitol. For determining the RDDP ac- 
tivity, poly(rC) . oligo(dG), at a final concentration of 0.1 units/ml, 
was used as a primer-template and labelled deoxynucleotide 
triphosphate was [‘H]dGTP (spec. act. 1100-1300 cpm/pmol) at a 
final concentration of 5 PM. For HIV-1 RT DDDP assay activated 
herring sperm DNA (prepared according to Spanos et al. [9]) was us- 
ed as the transcribed DNA at a final concentration of 20 pg/ml. The 
three unlabelled deoxynucleotides triphosphates dTTP, dATP and 
dCTP, were used at final concentrations of 50rM each and 
[‘H]dGTP was at 5 pM (spec. act. 1110-1300 cpm/pmol). 
3. RESULTS 
Substances that inhibit in vitro the unique HIV-RT 
catalytic activities are likely to fall into one of three dif- 
ferent categories: (i) Compounds that block all RT- 
catalytic activities, i.e., the RNA-dependent DNA 
polymerase (RDDP) and DNA-dependent DNA 
polymerase (DDDP), as well as the ribonuclease H 
(RNase H) activities associated with retroviral reverse 
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Table I 
The effect of different avarol and avarone derivatives on HIV-l 
RT-associated RDDP and RNase H activities 
HIV-l RT enzymatic activity (olo) 
RDDP” RNase H 
Avarone A 27 (6.8) 46 
Avarone B 30 (5) 59 
Avarol C 100 (S50) 86 
Avarone D 98 (,50) 96 
Avarone E 9 (1.0) 6 
Avarol F 28 (7.0) 0 
a The figures in parentheses are the 1% values calculated for the 
inhibition of HIV-l RT-associated RDDP activity by the different 
compounds. These values express the inhibitor concentrations in 
@g/ml 
The inhibition of RDDP and RNase H activities by the different 
avarones and avarols were performed at concentrations of 10 sg/ml 
and 50 fig/ml, respectively. All residual activities are expressed as a 
percentage of the activities of the control samples with no inhibitor. 
Activity of 100% corresponds to 125 units and 50 units of enzyme for 
RDDP and RNase H, respectively 
transcriptases. (ii) Inhibitors of the DNA polymerases 
exhibiting little or no effect on the RNase H function. 
(iii) Compounds that block the RNase H activity 
without significantly affecting the DNA polymerase 
function. In the present study we have chosen to ex- 
amine the effects of several marine natural products of 
the avarol and avarone group (see structural formulas 
in Fig. 1) on the different catalytic functions of HIV-l 
RT. Compounds defined as effective inhibitors were 
those found to inhibit more than 50% of either one of 
the catalytic activities associated with HIV-l RT at a 
final inhibitor concentration of either lOpg/ml (for 
RDDP and DDDP activities) or 50pg/ml (for RNase 
H). As can be seen in Table I, 4 of these compounds, 
avarone A (3 ‘-hydroxy avarone), avarone B (4’ ,6’-di- 
hydroxy avarone) and avarone E (6 ’ -hydroxy-4’ -meth- 
oxy-avarone) and avarol F (6’ -hydroxy avarol) were 
found to inhibit HIV-l RT associated RDDP. RDDP 
activity was impaired by more than 70% of its initial 
activity in the presence of the derivatives designated A, 
B and F, and by 91% in the presence of avarone E. The 
ICSO values (inhibitor concentrations yielding 50% 
inhibition of the enzymatic activities) determined from 
the dose-dependent curves were approximately 6.8, 5.0, 
1 .O and 7.0 rg/ml for avarones A, B, E and avarol F, 
respectively. Contrariwise, the two derivatives, avarol 
C (6 ’ -acetoxyavarol) and avarone D (6 ’ -acetoxyava- 
rone), were devoid of any significant activity against 
HIV-l RT associated RDDP (Table I). Avarones A and 
B exhibited only a moderate activity against RT- 
associated RNase H (54% and 41% inhibition at 
50 pg/ml, respectively) whereas avarone E and avarol F 
effectively inhibited this activity (by 94% and lOO%, 
respectively, at 50 pg/ml inhibitor). Considered 
Volume 269, number 1 FEBS LETTERS August 1 ,990 
AVARONE E (pg/ml) 
0 IO 25 30 40 50 
AVAROL F ()rg/ml) 
Fig. 2. Dose-response curves of HIV-1 RT inhibition by avarone E 
(A) and avarol F (B). Assay conditions are as described in section 2. 
The 100% enzymatic activity for RDDP (0), DDDP (0) and RNase 
H (A) activities correspond to 120, 10 and 55 units, respectively. 
together, it is apparent hat avarone E and avarol F are 
the most potent inhibitors out of the 6 derivatives 
analyzed. Therefore, these two compounds were 
selected for further study as representatives of the ac- 
tive inhibitors. We have measured the extent of the in- 
hibition of the three catalytic activities associated with 
HIV-l RT as a function of inhibitor concentrations. As 
can be seen in Fig. 2A, B, all three functions associated 
with HIV-l RT (i.e., RDDP, DDDP and RNase H) 
were susceptible to the inhibitory effects of avarone E, 
and avarol F. The ICSO values determined from these 
dose response curves for each enzymatic activity were 
in the case of avarone E 1 /cg/ml, 6 pg/ml and 
14pg/ml and in the case of avarol F 7 hg/ml, 
4.5 pg/ml and 14.5 ag/ml for RDDP, DDDP and 
RNase H activities, respectively. 
3.1. Analysis of the mode of inhibition and determina- 
tions of kinetic constants 
We have studied the kinetics of inhibition of the most 
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Fig. 3. Double reciprocal plots of the effect of increasing 
concentrations of both dGTP (A) and the primer-template 
poly(rC) . oligo(dG) (B) on the incorporation of [‘H]dGTP by HIV-l 
RT, in the absence ( W) or in the presence of 2 fig/ml (A) and 4 pg/ml 
(0) of avarone E. The reactions were carried out for 10 min at 37°C 
under the conditions described in section 2. 
potent inhibitor avarone E by analyzing the initial rates 
of the DNA polymerizing reactions as a function of in- 
creasing concentrations of either the template-primer 
or the deoxynucleoside-triphosphate substrate (in the 
absence or in the presence of inhibitor at final concen- 
trations of 4 or 8 pg/ml. The values of V,,,,, and K,,, 
were determined from the double-reciprocal plots of 
velocity rates versus substrate concentrations (Fig. 3). 
The Km values for avarone E were calculated to be 
2.8 PM for dGTP and 1.6 pg/ml for po- 
ly(rC) - oligo(dG) irrespective of the presence of the in- 
hibitor, whereas the V,,, values were suppressed as a 
function of the presence of avarone E. Therefore, the 
mode of inhibition of RT activity by avarone E is non- 
competitive with respect to both dGTP and primer- 
template, i.e., reduced V,,, and unaltered K,,, values. 
Thus, the results suggest hat avarone E binds HIV-l 
RT molecules at sites different from the binding sites of 
either one of the substrates for DNA synthesis. 
4. DISCUSSION 
In the scientific effort to develop anti-AIDS drugs, a 
considerable number of compounds with diverse 
molecular properties have been so far tested for their 
133 
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anti-HIV RT activities. These include deoxynucleoside 
analogues (such as 3 ’ azidothymidine-AZT), or 
2 ’ ,3 ’ -dideoxynucleosides (such as dideoxynosine or 
dideoxycytidine) that inhibit the viral RT in the form of 
5’-triphosphonucleosides [lo-141, foscarnet [15], 
suramine [16], rifabutine [18], or HPA 23 [18]. Unfor- 
tunately, some of the drugs were found to be either in- 
sufficiently potent or too toxic to be considered for 
further development as anti-HIV drugs. To date, the 
only drug that was approved for clinical use is AZT, 
despite its known side effects [19]. The emergence of 
AZT-resistant HIV strains in patients treated with the 
drug has serious implications when considering it for 
wider use in the future [20]. This highlights the urgent 
need for the development of alternative drugs against 
AIDS. 
In the course of screening for novel natural products 
with anti-HIV-l RT activities we have found that com- 
pounds related to avarol and avarone were effective in- 
hibitors. Avarol and avarone were previously reported 
to possess a variety of biological activities such as: (i) 
a potent antileukemic activity both in vivo and in vitro 
[21]; (ii) T-lymphotropic cytostatic activity in vitro 
[22]; (iii) anti-HIV activity in vitro in the H-9 cell 
system [23]. The results presented in this communica- 
tion reveal another facet of the biological activities 
associated with this group of natural substances. Four 
avarol and avarone derivatives designated A, B, E, F, 
out of which B, E and F are novel secondary 
metabolites (Kashman et al., personal communication), 
were found to be potent inhibitors of HIV-l RT in 
vitro. Avarone A and avarol F inhibited the enzyme ac- 
tivities most effectively. The two derivatives with 
6’ -acetyl-substituents (avarol C and avarone D) were 
devoid of any significant inhibitory activity against 
reverse transcriptase. This is in line with the results 
previously reported for unmodified avarol and avarone 
(also lacking the 6’-hydroxyl group) that exhibited no 
significant inhibitory activities against MuLV and 
HIV-l RT DNA polymerase functions as well as 
against mammalian DNA polymerase [24]. When taken 
together, it seems that the hydroxyl group at the ortho 
position to the carbonyl group of the quinone ring (as 
in the case of the derivatives A, B, E and F) is a re- 
quisite for inhibitory activity of these compounds. 
Similarly, we have recently found that in the case of 
another natural sesquiterpenoid, illimaquinone, the in- 
hibitory site of the compound is an hydroxyl group at 
the ortho position to the carbonyl group of the quinone 
ring. However, in this case the inhibition effect was 
restricted mainly to the RNase H function of HIV-l RT 
(submitted). Considered together, we believe that the 
identification of the inhibitory site of a compound is an 
important step towards the rational design of new po- 
tent anti-HIV and possibly anti-AIDS drugs. 
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